Results 41 to 50 of about 21,159,025 (295)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani +7 more
wiley +1 more source
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs
Haematologica, 2017 Histone methylation and demethylation regulate B-cell development, and their deregulation correlates with tumor chemoresistance in diffuse large B-cell lymphoma, limiting cure rates. Since histone methylation status correlates with disease aggressiveness
Rohit Mathur +9 more
doaj +1 more source
I INCREASED RISK OF LYMPHOMA IN MEN INFECTED WITH TUBERCULOSIS
Mediterranean Journal of Hematology and Infectious Diseases, 2021 Purpose: To identify factors associated with lymphoma in patients with anterior Mycobacterium tuberculosis (TB). Methods: A retrospective case-control analysis was performed in a highly tuberculosis-endemic area.
guangliang Chen
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk +10 more
wiley +1 more source
Ibrutinib in B-cell lymphoma: single fighter might be enough?
Cancer Cell International, 2020 Background In recent years, the B cell receptor (BCR) signaling pathway has become a “hot point” because it plays a critical role in B-cell proliferation and function. Bruton’s tyrosine kinase (BTK) is overexpressed in many subtypes of B-cell lymphoma as
Chao Xue +5 more
doaj +1 more source
Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin +17 more
wiley +1 more source
Haematologica, 2019 T-cell/histiocyte-rich large B-cell lymphoma is a rare aggressive lymphoma showing histopathological overlap with nodular lymphocyte-predominant Hodgkin lymphoma.
Bianca Schuhmacher +12 more
doaj +1 more source
Journal of Medical Case Reports, 2020 Background Epstein-Barr virus is associated with many human hematopoietic neoplasms; however, Epstein-Barr virus-positive mucosa-associated lymphoid tissue lymphoma is extremely rare.
Vadim R. Gorodetskiy +6 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann +8 more
wiley +1 more source
Molecular mechanisms of follicular lymphoma and its transformation [PDF]
, 2011 PhDFollicular lymphoma (FL) is the second most common form of non-Hodgkin lymphoma and at least a third of cases undergo aggressive transformation (t-FL), most frequently to diffuse large B-cell lymphoma.
Wrench, David John
core +2 more sources